Altamira Therapeutics announced the publication of a peer-reviewed article in Nature Immunology highlighting the important role of the Zbtb46 gene in the control of tumor growth and demonstrating a significant reduction in tumor growth in vivo through treatment with Zbtb46 mRNA delivered with Altamira’s SemaPhore(TM) nanoparticle technology. The treatment effect was potentiated when combined with anti-PD1 immune checkpoint inhibition, inducing long-term remission and promoting immunological memory. The research was conducted by a group around Professor Kyunghee Choi of the Pathology & Immunology Department of Washington University School of Medicine. The paper found: Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore(TM) delivery technology results in significant reduction in tumor growth; Combination of nanoparticles with immune checkpoint inhibitor (anti-PD1) shows even more pronounced improvement, synergistic control of tumor growth with long-term complete remission of tumor in many cases
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTO:
- Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
- Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
- Altamira Therapeutics announces publication of preclinical data on SOD2 mRNA
- Altamira Therapeutics announces publication on betahistine
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management